Adenoviruses Mutated In The VA Genes For Cancer Treatment
AssigneeOncolytics Biotech Inc.
InventorsRamon Alemany Bonastre, Manel Maria Cascallo Piqueras
Life of this patent
Estimating the term…
Abstract
This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.
Claims25
1-11. (canceled)
An adenovirus having mutated VAI and VAII RNA genes, wherein said adenovirus is defective in its VAI and VAII virus-associated RNAs and will selectively replicate in cells of said cancer, and wherein said adenovirus further has one or more additional mutations to obtain selective replication in tumors.
An adenovirus comprising:
- (A) one or a combination of (i) a mutation within a VAI gene;
- (ii) a mutation in a sequence before a VAI gene that controls the expression of said gene;
- or (iii) a mutation in a sequence after a VAI gene that controls termination of transcription of said gene;
- (B) one or a combination of (i) a mutation within a VAR gene;
- (ii) a mutation in a sequence before a VAII gene that controls the expression of said gene;
- or (iii) a mutation in a sequence after a VAII gene that controls termination of transcription of said gene;
- and
- (C) one or more additional mutations to obtain selective replication in tumors.
- wherein said mutations (A) and (B) result in defective VAI and VAII virus-associated RNAs,
- and wherein said adenovirus will selectively replicate in cells of said cancer.
Dependencies are inferred from the claim text.